Top 50 Biotech Startup Investors in Switzerland (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
48 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Software, Artificial Intelligence | $20k–$2.5M |
|
Zürcher Kantonal Bank
VC Fund
|
38 | Switzerland, Germany, Japan | Seed, Series A, Series B | Health Care, Biotechnology, Medical Device | $1M–$20M |
|
Verve Ventures
VC Fund
|
20 | Switzerland, Germany, France | Seed, Series A, Series B | Software, Health Care, Biotechnology | $1.2M–$45M |
|
BioMedPartners
VC Fund
|
19 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $5.3M–$75M |
|
M Ventures
VC Fund
|
16 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Versant Ventures
VC Fund
|
15 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $5M–$107M |
|
VI Partners
VC Fund
|
14 | Switzerland, Germany, United States | Series A, Series B, Series C | Health Care, Biotechnology, Software | $3.2M–$100M |
|
Bernina BioInvest
VC Fund
|
13 | Switzerland | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.5M–$65M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
12 | Germany, Switzerland, United States | Seed, Series A, Pre-Seed | Software, Biotechnology, Information Technology | $790k–$31M |
|
EQT Life Sciences
VC Fund
|
12 | United States, Switzerland, The Netherlands | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$165M |
|
Eclosion SA
VC Fund
|
11 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
Novartis Venture Fund
VC Fund
|
11 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Schroder Adveq
VC Fund
|
10 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5M–$100M |
|
Sofinnova Partners
VC Fund
|
10 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
SICTIC
VC Fund
|
10 | Switzerland, Germany, Tanzania | Seed, Venture - Series Unknown, Pre-Seed | Software, Artificial Intelligence, Information Technology | $264k–$11M |
|
redalpine
VC Fund
|
9 | Germany, Switzerland, United Kingdom | Seed, Series A, Series B | Artificial Intelligence, Health Care, Biotechnology | $1.6M–$125M |
|
Kinled Holding
VC Fund
|
9 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $594k–$40M |
|
Kickfund
VC Fund
|
9 | Switzerland, France, Germany | Seed, Pre-Seed, Convertible Note | Health Care, Biotechnology, Manufacturing | $110k–$5.7M |
|
GoBeyond
VC Fund
|
8 | Switzerland, Germany, United Kingdom | Seed, Venture - Series Unknown, Series A | Software, Health Care, Information Technology | $495k–$5.1M |
|
Lichtsteiner Foundation
VC Fund
|
8 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
Index Ventures
VC Fund
|
7 | United States, United Kingdom, France | Series A, Series B, Seed | Software, Artificial Intelligence, SaaS | $1.5M–$102M |
|
Novo Holdings
VC Fund
|
7 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
4FOX Ventures
VC Fund
|
7 | Switzerland, United States | Series A, Seed, Series B | Medical Device, Medical, Health Care | $1.8M–$69M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
7 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Swisscom Ventures
VC Fund
|
6 | Switzerland, United States, United Kingdom | Series B, Series A, Series C | Software, SaaS, Information Technology | $2M–$80M |
|
Omega Funds
VC Fund
|
6 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Aglaia BioMedical Ventures
VC Fund
|
6 | The Netherlands, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Therapeutics, Pharmaceutical | $3.7M–$23M |
|
Broadview Ventures
VC Fund
|
5 | United States, Switzerland, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $1M–$45M |
|
Pfizer Venture Investments
VC Fund
|
5 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $12M–$120M |
|
Aargauische Kantonalbank
VC Fund
|
5 | Switzerland | Series B, Seed, Series A | Medical Device, Dental, Medical | $1.4M–$3.6M |
|
Founderful
VC Fund
|
5 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $810k–$24M |
|
Privilège Ventures
VC Fund
|
5 | Switzerland, Italy, France | Seed, Pre-Seed, Series A | Health Care, Software, Wearables | $667k–$7M |
|
Pureos Bioventures
VC Fund
|
5 | France, Switzerland, United States | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $7.1M–$125M |
|
Lakestar
VC Fund
|
4 | United Kingdom, Germany, United States | Seed, Series A, Series B | Software, Artificial Intelligence, Financial Services | $2.2M–$91M |
|
EVA Basel
VC Fund
|
4 | Switzerland | Seed, Series A | Biotechnology, Medical Device, Pharmaceutical | $1.9M–$3.7M |
|
Polytech Ventures
VC Fund
|
4 | Switzerland, United States, Spain | Seed, Series A, Series B | Software, Financial Services, FinTech | $500k–$10M |
|
Aravis Ventures
VC Fund
|
4 | Switzerland, United States, Denmark | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $4.4M–$80M |
|
Penny Schiffer
Angel
|
4 | Switzerland, Germany, United Kingdom | Seed, Series A, Venture - Series Unknown | Medical, Software, Health Care | $495k–$8M |
|
b2venture
VC Fund
|
4 | Germany, Switzerland, United Kingdom | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.2M–$52M |
|
OrbiMed
VC Fund
|
4 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9.8M–$160M |
|
Fongit Seed Invest
VC Fund
|
4 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1M–$3.3M |
|
Gilde Healthcare
VC Fund
|
4 | United States, The Netherlands, Germany | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $9.5M–$135M |
|
Endeavour Vision
VC Fund
|
4 | United States, Switzerland, France | Series C, Series B, Series A | Health Care, Medical, Biotechnology | $2.1M–$115M |
|
Neomed Management
VC Fund
|
4 | Switzerland, United States, Sweden | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $8.3M–$44M |
|
New Enterprise Associates
VC Fund
|
4 | United States, China, India | Series A, Series B, Series C | Software, Health Care, Biotechnology | $6M–$102M |
|
Inkef
VC Fund
|
4 | The Netherlands, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $3.1M–$86M |
|
Swisscanto Private Equity
VC Fund
|
3 | Switzerland, Denmark, Germany | Series B, Series C, Venture - Series Unknown | Health Care, Biotechnology, Manufacturing | $9.2M–$54M |
|
BlueOcean Ventures
VC Fund
|
3 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
Bpifrance
VC Fund
|
3 | France, United States, Switzerland | Seed, Venture - Series Unknown, Series A | Software, Health Care, Biotechnology | $752k–$34M |
|
BB Biotech Ventures
VC Fund
|
3 | United States, Switzerland, Italy | Series C, Series A, Series B | Biotechnology, Health Care, Medical | $1.1M–$132M |
| Access all 906 investors in Switzerland Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Software, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 275
- Round size: Seed $100k–$2.5M; Grant $20k–$125k; Debt Financing $99k–$531k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- Rivelock — Rivelock is a swiss conditional payment platform that secures payments between service providers and customers.
- SixtineAI — is an AI-driven clinical documentation and workflow assistant specifically designed for healthcare providers.
- Documenter AI — Complete AI copilot platform for enterprise project management, compliance automation, and business process automation. Deploy intelligent agents, automate workflows, and ensure compliance across all industries.
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 207
- Round size: Seed $1M–$6M; Series A $2.1M–$13M; Series B $1.9M–$20M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely actively investing — fresh fund, raised $150M in 2024
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 304
- Round size: Seed $1.2M–$11M; Series A $2.1M–$18M; Series B $3.9M–$45M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $61M in 2022
Portfolio highlights
- Piomic — Non-invasive treatment with minimal staff supervision to produce a durable structural, functional and cosmetic closure of hard-to-heal wounds.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
- Atana Elements — Atana is accelerating the exploration and development of flowing critical minerals and industrial gases. Atana uses a proprietary tech stack to identify and mature mineral resources quickly and effectively.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 88
- Round size: Series A $5.3M–$31M; Series B $5.3M–$75M; Series C $5.3M–$47M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $106M in 2018
Portfolio highlights
- T-CURX — T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 188
- Round size: Seed $2.4M–$24M; Series A $5.8M–$50M; Series B $13M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 333
- Round size: Series A $5M–$78M; Series B $12M–$105M; Series C $12M–$107M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $5M in 2024
Portfolio highlights
- Inari Medical — Inari Medical is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. They are focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. It hasdeveloped two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.The company was founded in 2011 and is headquartered in Irvine, California.
- Gate Bioscience — Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.
- Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 114
- Round size: Series A $3.2M–$23M; Series B $3.3M–$41M; Series C $7M–$100M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $110M in 2020
Portfolio highlights
- Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
- Pay by Shopping (deal united) — paybyshopping.com Domain Name is available to Buy. Grab this great Domain from Daaz. Daaz has the lowest transaction fees in the industry. See our list of GTLD's,CCTLD's, New GTLD's,3N's, 6N's, 3L's, 6L's etc.
- Sonic Emotion — Sonic Emotion Absolute 3DTM sound technology provides an innovative unique solution for an immersive natural 3D sound reproduction by implementing audio products with sound field control from only 2, 3, 4 or 6+ channels using a single compact device (and an optional subwoofer internal or external).
Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.5M–$20M; Series A $15M–$65M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 771
- Round size: Seed $790k–$6.9M; Pre-Seed $841k–$2.8M; Series A $3M–$31M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Extoll — EXTOLL, a leader in high-speed, ultra-low power SerDes and Chiplet connectivity, offers semiconductor IP with the smallest footprints and highest PPA. Serving global ASIC, SoC, and Chiplet markets, our portfolio includes tailored NoC (Network-on-Chip) and Die-to-Die solutions. EXTOLL drives innovation, enabling successful migration into the Chiplet Age.
- BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, The Netherlands
Investor stats
- Total investments: 189
- Round size: Series A $7.3M–$78M; Series B $11M–$114M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $282M in 2023
Portfolio highlights
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Vaderis Therapeutics — Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 234
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5M–$22M; Series B $11M–$73M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet.The website has over 500 designs ofeye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 353
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- EnginZyme — Enzymatic chemistry for cleaner ingredients in personal care, food and pharma. Enginzyme's patented EziG platform makes enzymes work at industrial scale.
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 301
- Round size: Seed $504k–$3.7M; Pre-Seed $264k–$2.7M; Venture - Series Unknown $1.2M–$11M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
- Prevision Medicine — Prevision Medicine AG is a oncology company that provides cancer therapy, tests living cancer cells, and deliver clinical insights.
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 203
- Round size: Seed $1.6M–$13M; Series A $3.2M–$33M; Series B $16M–$125M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $200M in 2024
Portfolio highlights
- telli — A world where every interaction is worth having. https://t.co/Qa65ENaxKL
- Arlequin AI — Unlock actionable insights from complex social data to drive strategic decisions using our AI models.
- Basecamp Research — Novel proteins from nature. We sample the most extreme and exciting places on the planet to build the world's largest knowledge graph of natural biodiversity.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 144
- Round size: Seed $594k–$14M; Series A $1.7M–$40M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- Cornea Sense — CorneaSense is a medtech startup developing a non-invasive, eye-based sensing device that measures ocular surface hydration to enable early detection and monitoring of conditions such as dry eye disease and systemic health disorders. The technology aims to provide real-time, objective eye biomarkers for improved clinical diagnosis and patient care.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, France, Germany
Investor stats
- Total investments: 51
- Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4M; Convertible Note $110k–$118k
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $80M in 2023
Portfolio highlights
- Bewelab SA — Bewe is a mobile game designed to reduce cravings, using neuroscience to automatically retrain your brain and effortlessly reclaim your health.
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Helix Robotics — We are building the first commercial soft manipulator
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 196
- Round size: Seed $495k–$5M; Series A $1.2M–$4.5M; Venture - Series Unknown $681k–$5.1M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
- LockStyler — LockStyler is providing a revolutionary, professional hair highlighting system which is much simpler, cleaner and quicker by 50% than anything existing
- Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth combines a wearable acoustic sensor with your sleep, stress and nutrition data to reveal how your lifestyle affects your digestive health.
- Allegria Therapeutics — Allegria Therapeutics is a Swiss biotech company targeting mast cells to redefine the treatment of allergic and inflammatory diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 1579
- Round size: Seed $1.5M–$16M; Series A $5M–$35M; Series B $12M–$102M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely actively investing — fresh fund, raised $400M in 2026
Portfolio highlights
- PanGenetics — PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases.PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employsa lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients
- Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
- The Cambridge Satchel Company — Beautiful leather satchels and music bags in a variety of sizes, colours - backpack or shoulder strap styles. Made in England, the traditional school satchel is back and looking better than ever.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 407
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
4FO Ventures
Show more...Investment focus
- Industry: Medical Device, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: Switzerland, United States
Investor stats
- Total investments: 23
- Round size: Seed $1.8M–$3.3M; Series A $1.8M–$11M; Series B $5.5M–$69M
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — Discover how Ecorobotix is revolutionizing precision agriculture with AI-driven field sprayers. Cut costs, boost yields, and farm smarter with precision ag technology.
- Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 108
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Cloverleaf Bio — Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A, Series C
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 158
- Round size: Series A $2M–$22M; Series B $2M–$60M; Series C $8.6M–$80M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Apono — Apono makes permission management to applications, infrastructure, and data repositories simple, secure and compliant.
- CDDS — The CDDS interceptor is an autonomous, kinetic counter drone designed to neutralize Group 1 and Group 2 Unmanned Aerial System (UAS) threats with speed and precision.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Pharmaceutical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Switzerland
Investor stats
- Total investments: 14
- Round size: Seed $3.7M–$3.7M; Series A $5.5M–$17M; Series B $21M–$23M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $65M in 2014
Portfolio highlights
- Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
- InteRNA Technologies — A Dutch clinical-stage biotech company InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery
- Sapreme Technologies — Enabling endosomal escape
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 85
- Round size: Seed $1M–$18M; Series A $1M–$20M; Series B $7M–$45M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Adient Medical — Medical Devices that Automatically Vanish - Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Viridian Therapeutics (Formerly MiRagen Therapeutics) — Committed to developing potential best-in-class medicines for people affected by Thyroid Eye Disease and other autoimmune and rare diseases.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 188
- Round size: Series A $12M–$100M; Series B $20M–$120M; Series C $15M–$102M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
- Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargauand the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.
Show more...Investment focus
- Industry: Medical Device, Dental, Medical
- Stage:Series B, Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 13
- Round size: Seed $1.5M–$3.6M; Series B $1.4M–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Aliunid — Aliunid is a cleantech startup that records, optimizes, and controls energy flows using real-time data.
- Mesh — MESH is automating rebar fabrication and construction processes using robotics and software. Our mission is to bring modern robotics to rebar industry.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 111
- Round size: Seed $1.5M–$14M; Pre-Seed $810k–$4.3M; Series A $3M–$24M
- Lead/follow: 56% lead, 44% follow
- Last fund: Likely still investing — raised $143M in 2024
Portfolio highlights
- Fusionality — Fusionality is a Swiss fusion-technology company focused on measurement, control, and data systems for fusion devices.They combine expertise in fusion physics, control engineering, AI/ML, simulation, diagnostics, and real-time software.Their goal is to help fusion companies and research labs operate devices more efficiently and accelerate thedevelopment of commercial fusion energy.
- Stellar Alpina — Stellar Alpina develops modular lunar landers and the RDRE propulsion modules that power them, combining rapid hardware iteration with a scalable platform approach for reliable missions from Earth orbit to the Moon.
- Exclaim Robotics — Autonomous mobile robots for the AI data center.
Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team
Show more...Investment focus
- Industry: Health Care, Software, Wearables
- Stage:Seed, Pre-Seed, Series A
- Geography: Switzerland, Italy, France
Investor stats
- Total investments: 24
- Round size: Seed $1M–$5.9M; Pre-Seed $667k–$1.6M; Series A $4.1M–$7M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $21M in 2022
Portfolio highlights
- Xsensio — Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
- ENANTIOS — ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities.
- Develop Players — Supporto clinico per ADHD e DSA online. Aiutiamo adulti, bambini e ragazzi con screening, potenziamento e percorsi psicologici personalizzati.
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 37
- Round size: Series A $12M–$123M; Series B $7.1M–$100M; Series C $22M–$125M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $205M in 2020
Portfolio highlights
- AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
- NovaGo Therapeutics — NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. A strategic partnership with Neurimmune provides access to a unique class of human-derived antibodies with exceptional therapeutic propertiesgenerated through their Reverse Translational Medicine™ (RTM™) technology platform.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Lakestar invests in founders and technologies shaping Europe's future, helping build resilience, sovereignty, and long-term growth in a changing world.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Financial Services
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 251
- Round size: Seed $2.2M–$19M; Series A $6.7M–$65M; Series B $17M–$91M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely actively investing — fresh fund, raised $300M in 2026
Portfolio highlights
- Exein — Exein develops embedded cybersecurity solutions designed to secure Internet of Things (IoT) and connected devices. The company provides a platform that integrates security directly into the firmware of embedded systems, enabling real-time threat detection, monitoring, and response. Exein’s technology focuses on runtime protection and behavioranalysis at the edge, helping manufacturers secure devices without requiring major hardware changes or external software agents. Its solution is compatible with widely used real-time operating systems (RTOS) and Linux-based environments, allowing for flexible integration across different devices. The company also offers tools for vulnerability assessment and threat intelligence tailored for firmware-level defense. Exein supports developers with APIs and SDKs to incorporate security features during the product development phase. Through its platform, the company addresses growing security risks in critical sectors such as automotive, industrial automation, and consumer electronics.
- Modulate — Modulate uses revolutionary machine learning to proactively detect and escalate toxic behavior in your game. ToxMod becomes an expert in your code of conduct and empowers your moderators to make the right decisions to protect your community from the worst behavior happening in voice chat in real time.
- Twin1 AI — Twin1 is a privacy-first platform that gives every professional an AI-powered digital twin to scale their expertise.
EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Pharmaceutical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 5
- Round size: Seed $1.9M–$3.7M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
- Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Software, Financial Services, FinTech
- Stage:Seed, Series A, Series B
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 53
- Round size: Seed $500k–$3.5M; Series A $2.1M–$10M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Switzerland, United States, Denmark
Investor stats
- Total investments: 19
- Round size: Series A $4.4M–$80M; Series B $6.8M–$33M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
- Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
- Hedera-22 — Explore the top online casino no verification withdrawal Australia sites. Fast payouts, crypto banking, and safe pokies at trusted no KYC casinos.
Penny Schiffer - CEO & Co-founder @ Raized.ai
Show more...Investment focus
- Industry: Medical, Software, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 34
- Round size: Seed $495k–$8M; Series A $1.2M–$6M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- Enterprise Bot — Cost-effective Conversational AI solutions transforming customer interaction for global enterprises. Discover cutting-edge chat, email, and voice tech.
- Scientific Visual — Scientific Visual supplies quality control workstations to visualize defects in non-polished sapphire such as watch covers, ingots and wafers.
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 278
- Round size: Seed $1.2M–$8.8M; Series A $3.4M–$23M; Series B $6.9M–$52M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely actively investing — fresh fund, raised $179M in 2026
Portfolio highlights
- LiveEO — LiveEO is the leading solution provider for AI-powered satellite-based monitoring of large infrastructure networks. Trusted worldwide.
- Everlab — The preventative health service of the future. Detect disease early, improve wellbeing, and optimise performance.
- Flyboard — Human-level AI voice agents at a fraction of the cost. Transform your customer engagement with intelligent automation.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 762
- Round size: Series A $9.8M–$116M; Series B $23M–$148M; Series C $19M–$160M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- CoGenesys — CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Bonovo Orthopedics —
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1M–$1.4M; Series A $2.3M–$3.3M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed builds CardioKit: live ultrasound that follows the heart during radiotherapy and gates the beam, whether the heart is the target or the organ to protect.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 131
- Round size: Series A $9.5M–$62M; Series B $14M–$135M; Series C $21M–$80M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely actively investing — fresh fund, raised $296M in 2026
Portfolio highlights
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- GT Medical Technologies — GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.
- Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series C, Series B, Series A
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 77
- Round size: Series A $2.1M–$30M; Series B $7M–$48M; Series C $12M–$115M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $375M in 2021
Portfolio highlights
- Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
- Venture Med Group — Create a dynamic website for your electrical services with Avada & WordPress. Showcase your expertise, services, and attract clients with engaging designs.
- Kestra Medical Technologies, Inc. — Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients.
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, Sweden
Investor stats
- Total investments: 45
- Round size: Series A $8.3M–$37M; Series B $21M–$42M; Series C $9.2M–$44M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — raised $51M in 2015
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, China, India
Investor stats
- Total investments: 2087
- Round size: Series A $6M–$55M; Series B $10M–$85M; Series C $15M–$102M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $468M in 2024
Portfolio highlights
- Zyngenia —
- ARRIS — High-volume producer of advanced carbon parts for drones, aerospace, cycling, and consumer applications. (Made in U.S.A. or Taiwan)
- Lithium Technologies — Lithium builds trusted relationships between the world’s best brands and their customers, helping people get answers and share their experiences. Brands like Microsoft, HP, Sephora, Virgin and Barclaycard and customers in more than 34 countries rely on Lithium to help them connect, engage, and understand their total community. With more than 100million monthly visits over all Lithium communities and 750 million online profiles scored by Klout, Lithium has one of the largest digital footprints in the world. Using that data and the company’s software, Lithium customers boost sales, reduce service costs, spark innovation, and build long-term brand loyalty and advocacy.
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Germany
Investor stats
- Total investments: 93
- Round size: Seed $3.1M–$24M; Series A $3.4M–$42M; Series B $8.2M–$86M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $562M in 2016
Portfolio highlights
- Silverflow — Silverflow offers global payment technology to power financial institutions.
- Provable Markets — A comprehensive suite of trading & trade management solutions for the front, middle, and back office
- Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
We invest in growth companies in the "late-stage venture/growth capital" phase, focussed on the technology and healthtech sectors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series B, Series C, Venture - Series Unknown
- Geography: Switzerland, Denmark, Germany
Investor stats
- Total investments: 35
- Round size: Series B $9.2M–$52M; Series C $22M–$54M; Venture - Series Unknown $20M–$47M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $204M in 2018
Portfolio highlights
- MedTrace Pharma — MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly.
- ANYbotics — ANYbotics provides autonomous legged robots for industrial applications to provide high availability and reliability in automated routine inspections.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3.1M; Series A $2.3M–$20M; Series B $4M–$16M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Augurix — Augurix was born out of the real-life experiences of living with Celiac Disease. In 2004, Cecile – a pediatrician with an MD and PhD in immunology – noticed her 18-month old son Simon exhibiting symptoms of the disease. As a professional and having been diagnosed herself some thirty years earlier, she was able to spot the early warning signs. ButCecile was also acutely aware that despite affecting almost 1 in 100 people, Celiac Disease was difficult to diagnose.Cecile and her husband Thierry became determined to find a way to change this, giving parents and their children the best chance of an accurate diagnosis and the ability to live their lives free of the often debilitating symptoms. Using Swiss medical expertise Augurix was founded in 2007, with a mission to provide primary care doctors with an easy-to-use, affordable tool, to lower the hurdle of diagnostics.In 2010 Simtomax® was launched – a rapid screening test for the early determination of Celiac Disease at the point-of-care – finally bringing Cecile’s vision to life. Today, Augurix is pursuing its vision by enlarging its diagnostics offer to other gastrointestinal diseases.
- RockFlow — RockFlow is an artificial intelligence fintech company headquartered in Singapore, with offices in 5 countries and regions worldwide. As a next-generation AI-native trading platform, RockFlow offers users a personalized AI investment assistant. It delivers real-time trading insights and position management services tailored to individual targetreturns, risk preferences, and other criteria.The team has a background in cross-border innovation and rich practical and continuous entrepreneurial experience in artificial intelligence, financial engineering, and technology industries. The core members of the company come from top technology companies and financial institutions such as Facebook, Baidu, ByteDance, Huawei, Intel, Vanguard Group, Goldman Sachs, CITIC Securities, and ORC. Many members graduated from top universities in the world, such as MIT, Imperial College London, University of California, Berkeley, and Columbia University.As an AI investment platform, RockFlow is committed to achieving financial equality through AI, allowing everyone to easily experience the joy of simple investment. The product has 9 languages and users are located in more than 30 countries and regions around the world.Since its inception, RockFlow has received $10 million Angel Round Financing led by BlueRun Ventures. Since its inception, RockFlow has been a major promoter of investment innovation, trusted by top global financial institutions and Silicon Valley dollar funds. Current partners include NASDAQ, HKEx, Refinitiv, NYSE, ICE, Interactive Brokers, and HSBC.
- official.fm — Music to discover and share.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1710
- Round size: Seed $752k–$6.1M; Series A $2.6M–$34M; Venture - Series Unknown $1.1M–$31M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $27M in 2025
Portfolio highlights
- Cube — Cube is a French accelerator for tech startups, particularly in Web3, blockchain, and innovation, rebranded from Cube3. It provides a 9-month program combining strategic mentoring, customized funding, media production, and investor networking to scale promising ventures.
- Ostrea — OSTREA is a pioneering company in the creation of high-performance materials based on bio-minerals: seashells.
- NeoXperiences — NeoXperiences develops technological solutions that bring audiences together around fun and interactive experiences.
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series C, Series A, Series B
- Geography: United States, Switzerland, Italy
Investor stats
- Total investments: 35
- Round size: Series A $1.1M–$24M; Series B $9M–$132M; Series C $3.3M–$66M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — raised $96M in 2009
Portfolio highlights
- Arvinas — Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
- Molecular Templates — Molecular Templates is a clinical-stage biopharmaceutical company developing engineered toxin bodies (ETBs) for the treatment of cancers.
- Rivus Pharmaceuticals — Rivus Pharmaceuticals, a leader in mitochondrial biology, is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity.
Biotech Investor funding in Switzerland at a glance
Stats across 1.2k deals from 906 investors.
Access all 906 investors in Switzerland Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 906 investors investing in Switzerland Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!